Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (2627)	11/18/1997 9:06:00 PM
From: MisterED	Respond to of 23519

Since Zonagen has a pill (Vasomax) and Pfizer has a pill (Viagra), who will benefit the most from the barage that Asensio delivered against Zonagen today? Not necessarily the short sellers, and your guess is as good as mine.

To: BigKNY3 who wrote (2627)	11/18/1997 9:07:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 23519

BigKNY3, I post before that Asencio will not go after Pfe so you could be calm and cool. Asencio goes after dubious companies and he is a short with a mission, to short till the last cent. Asencio is clearly a short, and he was very nice about Viagra (probably to stress that there is something good vs zona). Pfizer will survive this threat, I mean this thread. Vivus is going after the ED market niche, between orals and the neddles. The ones looking under the rocks are maybe some members of this thread, but not "Vivus". It is interesting that you want everything correct about posts but use "Vivus" to refer to comments in the tread. Believers of PR news are many around, including everything about viagra which is so far PR + the good prestige of the company + its excellence in research. But no data is out yet.